Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Quercetin (QT) is a potential bioflavonol and antioxidant with poor bioavailability and very low distribution in the brain. A new oral delivery system comprising of poly(n-butylcyanoacrylate) nanoparticles (PBCA NPs) was introduced to improve the oral bioavailability of QT and to increase its distribution in the brain. Physicochemical characteristics, in vitro release, stability in simulated gastric fluid and intestinal fluids, and pharmacokinetics and biodistribution studies of QT-PBCA NPs coated with polysorbate-80 (P-80) were investigated. OBJECTIVE: This study aimed to investigate the physicochemical characteristics, in vitro release, stability in simulated gastric fluid and intestinal fluids, and pharmacokinetics and biodistribution studies of QT-PBCA NPs coated with polysorbate-80 (P-80). RESULTS: The results showed that QT-PBCA NPs and QT-PBCA NPs coated with P-80 (QT-PBCA+P-80) had mean particle sizes of 161.1±0.44 nm and 166.6±0.33 nm respectively, and appeared spherical in shape under transmission electron microscopy. The mean entrapment efficiency was 79.86%±0.45% for QT-PBCA NPs and 74.58%±1.44% for QT-PBCA+P-80. The in vitro release of QT-PBCA NPs and QT-PBCA+P-80 showed an initial burst release followed by a sustained release when compared to free QT. The relative bioavailability of QT-PBCA NPs and QT-PBCA+P-80 enhanced QT bioavailability by 2.38- and 4.93-fold respectively, when compared to free QT. The biodistribution study in rats showed that a higher concentration of QT was detected in the brain after the NPs were coated with P-80. CONCLUSION: This study indicates that PBCA NPs coated with P-80 can be potential drug carriers for poorly water-soluble drugs. These NPs were observed to improve the drugs' oral bioavailability and enhance their transport to the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 2×
“QT-PBCA would mimic the lipoprotein particles and interact with the brain capillary endothelial cells and later be taken up by the same endothelial system.(15,17) PBCA NPs have been intensively investigated for decades, showing that coating the NPs with a nonionic surfactant such as P-80 makes them cross the BBB.”
Pharmacokinetics and bioavailability of quercetin glycosides in humans
Graefe, E. U., Wittig, J., Mueller, S., Riethling, A., Uehleke, B., Drewelow, B., Pforte, H., Jacobasch, G., Derendorf, H., & Veit, M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010366 · Cited by 649 · cited 1×
“63°C was not visible in QT-PBCA NPs, possibly due to the entrapment of drug molecules into PBCA NPs via molecular dispersion form.(47) It is also summarized that QT-PBCA NPs were in the noncrystalline state, but in highenergy amorphous form that supports the entrapment of QT in PBCA NPs.”
Development of Biodegradable Nanoparticles for Delivery of Quercetin
Kumari, A., Yadav, S. K., Pakade, Y. B., Singh, B., & Yadav, S. C. (2010) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2010.06.002 · Cited by 460
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., & Ravi Kumar, M. N. V. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-8418-y · Cited by 257
Joshi, S. A., Chavhan, S. S., & Sawant, K. K. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.07.007 · Cited by 235 · cited 1×
“%) acting as cryoprotectants, 29 using a lyophilizer (Lark, India).”
Cited by
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy
Yarla, N. S., Bishayee, A., Sethi, G., Reddanna, P., Kalle, A. M., Dhananjaya, B. L., Dowluru, K. S. V. G. K., Chintala, R., & Duddukuri, G. R. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.02.001 · Cited by 364
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Wróbel-Biedrawa, D., Grabowska, K., Galanty, A., Sobolewska, D., & Podolak, I. (2022) · Life · doi:10.3390/life12040591 · Cited by 95
“PBCA NPs coated with P-80 improved the oral bioavailability of Que by enhancing its transportation ability to the brain [35].”
BackgroundMethodPiccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Najafabadi, R. E., Kazemipour, N., Esmaeili, A., Beheshti, S., & Nazifi, S. (2018) · Advanced Biomedical Research · doi:10.4103/abr.abr_141_17 · Cited by 18
Metadata
- Authors
- Khan, Z., & Bagad, M.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2015-06
- Volume
- 10
- Pages
- 3921
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W1880202171
- Cited by
- 97
- References
- 6
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.